Showing results (1-10 of 170) with videos related to
Sort By:
Pageof 17
American Journal of Clinical Dermatology|March 4, 2020
Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?Patrick Schummer, Bastian Schilling, Anja GesierichFrontiers in Immunology|December 20, 2024
Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinomaValerie Glutsch, Patrick Schummer, Matthias Goebeler, et al.Melanoma Research|May 22, 2018
Early onset of diffuse melanosis cutis under pembrolizumab therapy illustrates the limitations of anti-PD-1 checkpoint inhibitorsAlexander Thiem, Patrick Schummer, Simon Ueberschaar, et al.Acta Dermato-Venereologica|January 20, 2026
Perioperative Pembrolizumab in Locally Advanced Melanoma: A Real-world Single-centre Retrospective StudySimon Goller, Tassilo Dege, Patrick Schummer, et al.Oncoimmunology|October 30, 2013
Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cellsBastian Schilling, Annette PaschenAmerican Journal of Clinical Dermatology|February 24, 2017
Next-Generation Sequencing to Guide Treatment of Advanced MelanomaKlaus G Griewank, Bastian SchillingDeutsche Medizinische Wochenschrift (1946)|November 30, 2020
[Endocrine side effects of cancer immunotherapy]Matthias Kroiß, Bastian Schilling, Timo DeutschbeinJournal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 25, 2026
Neoadjuvant therapy in skin cancer: current evidence and future perspectivesLea Daniello, Johannes Kleemann, Bastian SchillingOncology Letters|September 12, 2012
Adjuvant pegylated interferon α-2b therapy for melanomaBastian Schilling, Julia Vaubel, Dirk SchadendorfExpert Opinion on Biological Therapy|August 2, 2012
Induced and natural regulatory T cells in human cancerTheresa L Whiteside, Patrick Schuler, Bastian SchillingPageof 17